Telix Pharmaceuticals Lim... (TLX)

NEW YORK, NY / ACCESS Newswire / April 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:...

Telix Pharmaceuticals Limited (TLX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

TLX rolls out a new e-commerce platform connecting users to top retail pharmacies, aiming to boost savings, improve access, and expand its digital health services.

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term value through strategic investments and regulatory wins. Strong financial p...

Shares of Australia-based Telix Pharmaceuticals (TLX) rose 6% Friday as the U.S. Food and Drug Administration (FDA) approved the biopharma firm's agent for use in tests to screen for prostate cancer.

Telix Pharmaceuticals Limited (TLX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Telix Pharmaceuticals Limited (TLX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that...

Shares of Telix Pharmaceuticals surged to a record high on Friday after the company forecast annual bumper revenue, while its full-year earnings for 2024 soared more than ninefold.

Telix Pharmaceuticals Limited (OTCPK:TLPPF) FY 2024 Results Earnings Conference Call February 20, 2025 5:00 PM ET Company Participants Kyahn Williamson – Senior Vice President-Investor Relations and C...